RESTRICTED DEVICE ADVERTISING REG LIKELY TO EXEMPT INSULIN SYRINGES
This article was originally published in The Gray Sheet
RESTRICTED DEVICE ADVERTISING REG LIKELY TO EXEMPT INSULIN SYRINGES, home use lancets and at least 10 other devices, Byron Tart, director of the Promotion and Advertising Policy staff at FDA's Center for Devices and Radiological Health, said at a Sept. 12 meeting of the Food and Drug Law Institute in Washington, D.C. The syringes and "home diagnosis" lancets are on a preliminary list of 12 devices that, according to an outline of a notice of proposed rulemaking presented by Tart, do not meet the criteria for coverage under the restricted devices regulation.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.